Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China

被引:7
|
作者
Nie, Jing [1 ]
Wu, Huina [1 ]
Sun, Lei [1 ]
Ding, Yanjiao [1 ]
Luan, Yepeng [2 ]
Wu, Jiyong [1 ]
机构
[1] Shandong Second Prov Gen Hosp, Dept Pharm, Jinan, Shandong, Peoples R China
[2] Qingdao Univ, Med Coll, Sch Pharm, Dept Med Chem, Qingdao, Shandong, Peoples R China
关键词
fuzuloparib; niraparib; olaparib; cost-effectiveness; maintenance treatment; ovarian cancer; BRCA1/2; mutation; THERAPY; CANCER; TRIALS;
D O I
10.3389/fphar.2022.987337
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Maintenance therapy with the poly (ADP-ribose) polymerase inhibitors (PARPis) for platinum-sensitive recurrent ovarian carcinoma (OC) have proven to be effective compared with placebo. We aimed to evaluate the cost-effectiveness (CE) of maintenance fuzuloparib compared to routine surveillance (RS), niraparib and olaparib for platinum-sensitive recurrent OC from the Chinese healthcare systems.Method: A partitioned survival model with three-state (progression-free, progressed, death) was constructed utilizing TreeAge Pro 2011 software to evaluate the economic value of fuzuloparib, niraparib and olaparib maintenance treatment for platinum-sensitive recurrent OC based on the clinical data derived from FZOCUS-2, ENGOT-OV16/NOVA and ENGOT-Ov21/SOLO2. Transition probabilities were estimated from the reported survival probabilities in those trials. Cost and health preference data were derived from the literature. The quality-adjusted life-years (QALYs) and lifetime costs were measured for this analysis. A 5 years horizon and 5%/year discount rates were used. One-way analysis, and probabilistic sensitivity analysis (PSA) were performed to explore the model uncertainties.Results: Total cost of fuzuloparib, niraparib and olaparib were $31628.10, $48183.48 and $54605.54, whereas they had an incremental cost-utility ratio of $31992.69, $32216.08 and $23359.26 per additional progression-free survival (PFS) QALYs gained compared with RS, relatively. Model showed that maintenance fuzuloparib achieved at least an 85.5% probability of CE at the threshold of $37654.50/QALY. One-way sensitivity analysis revealed that the results were sensitive to the PFS and the price of medicines.Conclusion: Fuzuloparib was less cost-effective for patients with germline BRCA1/2 mutation and platinum-sensitive recurrent OC compared to olaparib, but was superior to niraparib from the Chinese healthcare systems perspective.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] New perspective on maintenance therapies for platinum-sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes
    Vergote, I.
    Bours, V.
    Blaumeiser, B.
    Baurain, J-F.
    FACTS VIEWS AND VISION IN OBGYN, 2016, 8 (03): : 161 - 167
  • [32] Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report
    Skof, Erik
    Stegel, Vida
    Dragos, Vita Setrajcic
    Blatnik, Ana
    Gregoric, Brigita
    Skerl, Petra
    Klancar, Gasper
    Klasinc, Anja Zagozen
    Bombac, Alenka
    Kraje, Mateja
    Novakovic, Srdjan
    GYNECOLOGIC ONCOLOGY, 2024, 190 : 104 - 112
  • [33] REAL WORLD OUTCOMES OF OLAPARIB MAINTENANCE THERAPY IN PATIENTS WITH BRCA1/2-MUTATED PLATINUM-SENSITIVE EPITHELIAL OVARIAN CANCER
    McLaren, A.
    White, M.
    Cartwright, D.
    Brown, J.
    Randhawa, M.
    Roxburgh, T.
    Glasspool, R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A166 - A166
  • [34] SOLO3: A randomized phase III trial of olaparib versuschemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCA1/2 mutation (gBRCAm).
    Lowe, Elizabeth S.
    Jayawardene, Deepthi
    Penson, Richard T.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
    Penson, Richard T.
    Villalobos Valencia, Ricardo
    Cibula, David
    Colombo, Nicoletta
    Leath, Charles A., III
    Bidzinski, Mariusz
    Kim, Jae-Weon
    Nam, Joo Hyun
    Madry, Radoslaw
    Hernandez, Carlos
    Mora, Paulo A. R.
    Ryu, Sang Young
    Milenkova, Tsveta
    Lowe, Elizabeth S.
    Barker, Laura
    Scambia, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (11) : 1164 - +
  • [36] ORZORA: Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status
    Pignata, Sandro
    Oza, Amit
    Hall, Geoff
    Pardo, Beatriz
    Madry, Radoslaw
    Cibula, David
    Klat, Jaroslav
    Montes, Ana
    Glasspool, Rosalind
    Colombo, Nicoletta
    Pete, Imre
    Herrero, Ana
    Romeo Marin, Margarita
    Ilieva, Rumyana
    Timcheva, Constanta
    Blakeley, Christopher
    Taylor, Rosie
    Barnicle, Alan
    Clamp, Andrew
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S29 - S29
  • [37] Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States
    Muston, Dominic
    Hettle, Robert
    Monberg, Matthew
    McLaurin, Kimmie K.
    Gao, Wei
    Swallow, Elyse
    Zhang, Su
    Kalemaj, Iden
    Signorovitch, James
    Moore, Kathleen
    GYNECOLOGIC ONCOLOGY, 2020, 159 (02) : 491 - 497
  • [38] Cost-effectiveness analysis of olaparib as a maintenance monotherapy for patients with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation: A United States payer perspective
    Muston, D. R. G.
    Monberg, M. J.
    McLaurin, K.
    Sackeyfio, A.
    Hettle, R.
    Signorovitch, J.
    Swallow, E.
    Gao, W.
    Zhang, S.
    Kalemaj, I.
    Moore, K. N.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 140 - 141
  • [39] Olaparib plus chemotherapy, followed by maintenance monotherapy, in women with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): BRCA1/2 mutation (BRCAm) and interim overall survival analyses
    Oza, A. M.
    Cibula, D.
    Oaknin Benzaquen, A.
    Poole, C. J.
    Mathijssen, R. H. J.
    Sonke, G. S.
    Mackay, H.
    Lowe, E. S.
    Read, J.
    Friedlander, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S712 - S713
  • [40] An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer
    Li, Ning
    Bu, Hualei
    Liu, Jihong
    Zhu, Jianqing
    Zhou, Qi
    Wang, Li
    Yin, Rutie
    Wu, Xiaohua
    Yao, Shuzhong
    Gu, Kangsheng
    Zhang, Hui
    Li, Guiling
    Pan, Hongming
    Wu, Qiang
    An, Ruifang
    Yang, Xinfeng
    Zhu, Yaping
    Wan, Xiaoping
    Duan, Wei
    Xiong, Jianping
    Guo, Hongyan
    Lou, Ge
    Wang, Jing
    Hu, Wenjing
    Zhang, Xin
    Meng, Yuanguang
    Zhang, Ben
    Wang, Yuting
    Wang, Quanren
    Wu, Lingying
    CLINICAL CANCER RESEARCH, 2021, 27 (09) : 2452 - 2458